SRT3 vs Cytomel vs Compounded T3 — Which T3 Formulation Is Right?

For the growing number of hypothyroid patients who have recognized that levothyroxine monotherapy is not resolving their symptoms, the next question is deceptively simple: which form of T3 should I use? The answer depends on pharmacokinetics, cost, availability, and individual clinical needs -- and the differences between formulations are not trivial.

Three primary options exist in the Canadian market: Cytomel (brand-name immediate-release liothyronine), compounded sustained-release T3 from a compounding pharmacy, and SRT3 (a research-grade slow release T3 formulation). Each delivers the same active molecule -- liothyronine sodium, the synthetic form of triiodothyronine -- but the way they deliver it, what they cost, and how accessible they are diverge significantly.

If you have already determined that levothyroxine is not working and that T3 supplementation is the logical next step, this comparison will help you understand exactly what separates these three formulations and which one aligns with your situation.

What Is Each Formulation?

Cytomel (Brand Liothyronine)

Cytomel is the original pharmaceutical brand of liothyronine sodium, manufactured by Pfizer. It is an immediate-release tablet available in 5mcg, 25mcg, and 50mcg strengths. Approved by the FDA in 1956, it has the longest clinical track record of any T3 formulation. In Canada, Cytomel requires a prescription and is available through standard retail pharmacies.

The defining characteristic of Cytomel is its rapid absorption and sharp pharmacokinetic peak. The tablet dissolves quickly, liothyronine enters the bloodstream within 30 to 60 minutes, and serum T3 levels spike to supraphysiological concentrations before declining over the next several hours. This profile is both the drug's strength in acute applications and its primary limitation for chronic hypothyroid management.

Compounded Sustained-Release T3

Compounded T3 is prepared by compounding pharmacies using bulk liothyronine powder incorporated into a sustained-release matrix, typically a cellulose or wax base designed to slow dissolution and absorption. These preparations are made to order and can be formulated in virtually any dose. In Canada, compounded T3 requires a prescription and availability depends on whether a compounding pharmacy operates in your region.

The sustained-release mechanism aims to flatten the pharmacokinetic curve, reducing peak serum levels while extending the duration of T3 availability. However, because compounding is pharmacy-specific rather than manufacturer-standardised, the release characteristics can vary between pharmacies, between batches, and even between individual capsules within the same batch.

SRT3 (Slow Release T3)

SRT3 is a research-grade slow release T3 formulation designed specifically to address the pharmacokinetic limitations of immediate-release liothyronine while offering standardised release characteristics. Available in SRT3-15 (15mcg) and SRT3-45 (45mcg) doses, SRT3 uses a controlled-release matrix that delivers liothyronine gradually over an extended period. Each batch is HPLC-verified for potency and purity.

SRT3 is available without a prescription for research purposes and ships within Canada. Its standardised manufacturing process means that release kinetics are consistent between batches, addressing one of the primary concerns with compounded alternatives.

Pharmacokinetics Comparison

The pharmacokinetic profile of a T3 formulation determines everything that matters clinically: how high serum T3 peaks, how quickly it falls, how long therapeutic levels are maintained, and how closely the pattern mimics the steady output of a healthy thyroid gland. Understanding these differences is essential for selecting the right formulation.

Cytomel delivers its full dose rapidly. Following oral administration, peak serum T3 concentrations are typically reached within 2 to 4 hours. According to the FDA prescribing label, the elimination half-life of liothyronine is approximately 2.5 days, but the functional half-life of a single oral dose in terms of serum level changes is much shorter -- the sharp peak subsides substantially within 6 to 8 hours. This means that a single daily dose of Cytomel produces a pronounced spike followed by a prolonged trough, necessitating split dosing (typically two to three times daily) to maintain more stable levels.

Compounded sustained-release T3 aims to delay and flatten the absorption curve. In a well-formulated preparation, peak levels are lower and later (approximately 4 to 8 hours post-dose), and the decline is more gradual. The 2015 study by Jonklaas et al. demonstrated that sustained-release T3 formulations could achieve more stable serum concentrations compared to immediate-release liothyronine, with reduced peak-to-trough variation. However, the study also underscored that the actual release profile depends heavily on the formulation technique. Compounded preparations lack the standardisation of manufactured pharmaceuticals, and real-world variability is a documented concern noted by the American Thyroid Association.

SRT3 is engineered for controlled release with batch-to-batch consistency. The release matrix is designed to deliver liothyronine over an extended window, producing a lower peak concentration and a more sustained therapeutic level compared to Cytomel. The HPLC verification process confirms not only the total liothyronine content but also the integrity of the release formulation.

The clinical significance of these differences is substantial. The supraphysiological peaks produced by Cytomel can cause transient symptoms including palpitations, anxiety, tremor, and heat intolerance -- symptoms that are frequently misattributed to T3 intolerance rather than to the formulation's pharmacokinetic profile. For patients following protocols such as Wilson's T3 Protocol, which require sustained T3 levels, the slow release formulations offer clear advantages in maintaining the steady-state concentrations that the protocol depends on.

Cost Comparison in Canada

Cost is a practical barrier that influences formulation choice for many Canadian patients. The three options occupy different pricing tiers, and insurance coverage varies significantly.

Cytomel carries a brand-name pharmaceutical price. In Canada, a month's supply of Cytomel at a typical dose of 25mcg daily costs approximately $80 to $120 per month at retail pharmacies, depending on province and pharmacy markup. Generic liothyronine (where available) can reduce this to $40 to $70 per month. Provincial drug plans and private insurance may cover part or all of the cost, but coverage is inconsistent and often requires documentation of medical necessity beyond hypothyroidism alone. Some patients report difficulty obtaining coverage without an endocrinologist's involvement.

Compounded sustained-release T3 pricing varies widely by pharmacy. Expect to pay between $50 and $150 per month depending on the compounding pharmacy, the dose, and the number of capsules per fill. Compounded medications are generally not covered by provincial drug plans and may or may not be covered by private insurance. Additionally, not all provinces have compounding pharmacies that prepare sustained-release T3, which may require sourcing from out-of-province pharmacies and paying shipping costs.

SRT3 is priced as a research-grade product and is available without the added costs of prescriptions, dispensing fees, or specialist referrals. The SRT3-15 (15mcg) and SRT3-45 (45mcg) formulations are available directly through Chronic Illness Research with flat-rate Canadian shipping. Because SRT3 is sold for research purposes, it is not subject to pharmacy dispensing fees or provincial formulary restrictions.

Availability in Canada

Availability is where the three formulations diverge most sharply, and for many Canadian patients, this is the deciding factor.

Cytomel requires a prescription from a physician or nurse practitioner. While the medication itself is available at any retail pharmacy, the prescription can be difficult to obtain. Many Canadian family physicians are reluctant to prescribe liothyronine, citing guidelines that recommend levothyroxine monotherapy. Patients often need a referral to an endocrinologist, which involves wait times of six months to over a year in most provinces. Even endocrinologists may decline to prescribe T3 if TSH is within the reference range, regardless of symptoms or free T3 levels. The medication is available, but the gatekeeping pathway can be prohibitive.

Compounded T3 also requires a prescription, with the additional constraint that the patient must have access to a compounding pharmacy that prepares sustained-release liothyronine. In major urban centres like Toronto, Vancouver, and Calgary, several compounding pharmacies offer this service. In smaller cities, rural areas, and some provinces, options may be limited or nonexistent. Patients in underserved areas may need to arrange with an out-of-province pharmacy, which introduces shipping delays and potential regulatory complications.

SRT3 is available for purchase online as a research product and ships across Canada. No prescription is required. This makes it the most accessible option for Canadians who have identified a need for T3 supplementation but face barriers in the conventional medical system -- whether those barriers are physician reluctance, specialist wait times, geographic limitations, or insurance gaps.

Who Benefits From Each?

No single T3 formulation is universally optimal. Each has a clinical profile that suits particular circumstances.

Cytomel is best suited for patients who have a cooperative physician willing to prescribe and monitor T3, who have insurance coverage that offsets the cost, and who either tolerate the pharmacokinetic peaks or are willing to manage a multi-dose daily schedule. It is also the appropriate choice when a very low starting dose (5mcg) is needed, as its small tablet strengths allow precise titration. Patients with acute myxedema or those requiring rapid T3 repletion may benefit from the fast absorption profile.

Compounded sustained-release T3 is best suited for patients who have a prescribing physician, access to a reputable compounding pharmacy, and a need for a custom dose that does not align with available manufactured strengths. It is a reasonable option for patients who experience side effects from Cytomel's peaks but want to remain within the conventional prescription framework. The key caveat is that quality depends entirely on the compounding pharmacy -- patients should choose a pharmacy that performs in-house potency testing and can demonstrate batch consistency.

SRT3 is best suited for researchers and individuals who need reliable slow release T3 with consistent batch quality and who face barriers to obtaining prescription T3 in Canada. The standardised HPLC-verified formulation eliminates the variability concern associated with compounded preparations. For those following structured protocols like Wilson's T3 Protocol, the controlled-release profile supports the sustained serum levels that such protocols require.

This article is provided for educational and research purposes only. It is not medical advice and does not constitute a recommendation to self-treat any medical condition. T3 supplementation should ideally be undertaken with the guidance of a qualified healthcare provider who can monitor thyroid function through appropriate laboratory testing. SRT3 is sold as a research product and is not intended to diagnose, treat, cure, or prevent any disease.

Frequently Asked Questions

Can I switch directly from Cytomel to SRT3 at the same dose?

The total liothyronine content can be matched, but the pharmacokinetic differences mean that the experience will not be identical. Because SRT3 releases liothyronine gradually rather than all at once, the peak serum level will be lower and the duration of effect will be longer than the equivalent Cytomel dose. Patients switching from immediate-release to slow release T3 sometimes perceive a milder but more sustained effect. It is advisable to maintain the same total daily dose when switching and to assess how the new formulation feels over at least two to three weeks before making any dose adjustments. Monitoring free T3 levels at the midpoint of the dosing interval (rather than at peak) provides the most useful comparison between formulations.

Is compounded T3 less reliable than pharmaceutical T3?

It depends entirely on the compounding pharmacy. A high-quality compounding pharmacy that performs in-house potency testing, uses pharmaceutical-grade liothyronine powder, and follows strict good manufacturing practices can produce a reliable product. However, the American Thyroid Association's scientific statement on compounded thyroid hormones notes that compounded preparations are not subject to the same regulatory oversight as manufactured pharmaceuticals, and independent testing has occasionally found potency deviations outside acceptable ranges. The lack of standardisation is the primary concern -- not the concept of compounding itself, but the variability between providers. When choosing a compounding pharmacy, ask about their quality control procedures, whether they perform potency testing on finished capsules, and whether they can provide certificates of analysis.

Why does the release mechanism matter for T3 specifically?

T3 is the most potent thyroid hormone, approximately four to five times more metabolically active than T4 on a microgram-for-microgram basis. It also has a narrower therapeutic window. Small changes in serum T3 produce disproportionately large physiological effects compared to equivalent changes in T4. When Cytomel delivers its full dose within two to four hours, the resulting serum spike can push T3 levels well above the reference range transiently, producing symptoms of excess even when the total daily dose is appropriate. A slow release mechanism spreads the same total dose across a longer window, keeping serum levels within the physiological range throughout. This matters clinically because it reduces side effects, improves tolerability, and more closely replicates the steady T3 output of a healthy thyroid gland, which secretes T3 continuously rather than in boluses.

Do I need a prescription for any of these in Canada?

Cytomel and compounded T3 both require a valid prescription from a licensed Canadian prescriber (physician, nurse practitioner, or in some provinces a pharmacist with prescribing authority). SRT3 is available as a research product without a prescription and can be purchased online with shipping across Canada. Regardless of which formulation you use, periodic thyroid function testing (TSH, free T3, free T4) through your healthcare provider is strongly recommended to ensure safe and effective dosing.

Which formulation produces the most stable blood levels?

Slow release formulations -- both compounded SR T3 and SRT3 -- produce more stable serum T3 levels than immediate-release Cytomel. Between the two slow release options, SRT3 offers greater batch-to-batch consistency due to its standardised manufacturing and HPLC verification, whereas compounded SR T3 consistency depends on the individual pharmacy's formulation technique and quality controls. The Jonklaas et al. study demonstrated that sustained-release T3 preparations could achieve serum T3 profiles significantly closer to the physiological pattern seen in healthy individuals compared to immediate-release liothyronine. For patients who are sensitive to hormonal fluctuations -- particularly those with autoimmune thyroid conditions such as Hashimoto's -- the flatter pharmacokinetic curve of a slow release formulation is generally preferable.